Cours InMed Pharmaceuticals Inc. Toronto S.E.
Actions
IN
CA4576376012
Recherche biotechnologique et médicale
CA 2024 * | 7,3 M 5,33 M 4,87 M | CA 2025 * | 9,12 M 6,67 M 6,09 M | Capitalisation | 1,91 M 1,39 M 1,27 M |
---|---|---|---|---|---|
Résultat net 2024 * | - | Résultat net 2025 * | - | VE / CA 2024 * | 0,26 x |
Trésorerie nette 2024 * | - 0 0 | Trésorerie nette 2025 * | - 0 0 | VE / CA 2025 * | 0,21 x |
PER 2024 * |
-
| PER 2025 * |
-
| Employés | 13 |
Rendement 2024 * |
-
| Rendement 2025 * |
-
| Flottant | 98,64% |
Dernier transcript sur InMed Pharmaceuticals Inc.
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
Eric Adams
CEO | Chief Executive Officer | 61 | 16/06/16 |
Chief Operating Officer | - | 05/11/18 | |
Colin Clancy
IRC | Investor Relations Contact | - | - |
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
Janet Grove
BRD | Director/Board Member | 57 | 11/02/22 |
Eric Adams
CEO | Chief Executive Officer | 61 | 16/06/16 |
Andrew Hull
CHM | Chairman | 61 | 12/09/16 |
Varia. 1 janv. | Capi. | |
---|---|---|
-2,31% | 103 Md | |
+0,56% | 95,28 Md | |
+1,69% | 22,15 Md | |
-17,37% | 21,02 Md | |
-9,30% | 18,15 Md | |
-41,01% | 16,74 Md | |
-14,85% | 16,05 Md | |
+3,21% | 13,68 Md | |
+33,54% | 12,17 Md |